You are here:

Archived: prucalopride (Resolor)

Advice

Following a full submission:

prucalopride 1mg and 2mg tablet (Resolor) is not recommended for use in NHSScotland.

Indication under review: symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.

There were weaknesses in the clinical data as in the pivotal studies the majority of patients did not achieve the primary or secondary outcome measures and the exclusion criteria applied limit the ability to assess the likely clinical effectiveness of prucalopride in the target treatment population. In addition, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: prucalopride (Resolor)
SMC Drug ID: 653/10
Manufacturer: Movetis UK
Indication: Chronic constipation in women in whom laxatives fail to provide adequate relief
BNF Category:
Sub Category: 1.6 Laxatives
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 December 2010

Current Advice

Resubmission 11 July 2011

Back